MedTrace Logo

Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy

NCT03689556 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-04-06

No results posted yet for this study

Summary

We aim, in this study, to examine whether reduction of FLT PET derived SUV before and after carbon ion radiotherapy can predict the treatment response and survivals for patients with locoregionally recurrent nasopharyngeal carcinoma.

Conditions

  • Recurrent Nasopharyngeal Carcinoma

Interventions

DIAGNOSTIC_TEST

FLT PET/CT

Patients will receive 3'-deoxy-3'-\[18F\]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.

Sponsors & Collaborators

  • Shanghai Proton and Heavy Ion Center

    lead OTHER

Principal Investigators

  • Jiade J Lu, MD · Shanghai Proton and Heavy Ion Center,Shanghai, SPHIC

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2023-08-31
Completion
2024-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03689556 on ClinicalTrials.gov